Jianming Guo

Tongji University — China

Medicine · Health Sciences

37h-index5.0kcitations349works2.32yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(107), Bladder and Urothelial Cancer Treatments(84), Cancer Immunotherapy and Biomarkers(80), Renal and related cancers(44), Epigenetics and DNA Methylation(28)

Publications346 total

Anatomically-guided Masked Autoencoder with Domain-Adaptive Prompting (AMAP) for multimodal cerebral aneurysm detection and segmentation

npj Digital Medicine·2025Open Access

Research on high-speed rail transfer intelligent recommendation system based on Python

2025

The CT-based deep learning model outperforms traditional anatomical classification models in preoperatively predicting complications and risk grade in partial nephrectomy

World Journal of Urology·2025

Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability

3 cited

Frontiers in Oncology·2025· 3 citedOpen Access

Supplementary Figure 15 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 6 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 7 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 18 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 8 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 11 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Tables from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 1 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 3 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 14 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 10 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Data from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 16 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 17 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 13 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure 5 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

2025Open Access

page 1 of 18Next →

Frequent Co-authors

Li Liu(18), Jiejie Xu(16), Yu Xia(15), Qi Bai(14), Yu Zhu(11), Ying Xiong(10), Qilai Long(10), Han Zeng(9), Zewei Wang(9), Le Xu(9), Bo Dai(9), Yang Qu(8), Jiajun Wang(8), Zhaopei Liu(7), Quan Zhou(7), Zhiyuan Lin(6), Yuan Chang(6), Weijuan Zhang(6), Yiwei Wang(5), Xinan Sheng(5)